

ANTI-MATRIX METALLOPROTEINASE-11 (MMP-11), N-TERMINAL

Developed in Rabbit, Affinity Isolated Antibody

Product Number M 0806

ProductInformation

Product Description

Anti-Matrix Metalloproteinase-11 (MMP-11) is developed in rabbit using a synthetic peptide corresponding to the N-terminal of human MMP-11 (stromelysin-3) as immunogen. Affinity isolated antigen specific antibody is obtained from rabbit anti-MMP-11antiserum by immuno-specific purification which removes essentially all rabbit serum proteins, including immunoglobulins, which do not specifically bind to the peptide.

Rabbit Anti-MMP-11, N-terminal may be used for the detection and localization of MMP-11 by various immunochemical techniques such as immunoblotting, immunoprecipitation, immunohistochemistry and ELISA.

Rabbit Anti-MMP-11, N-Terminal specifically binds to MMP-11 and does not cross-react with the other MMP family members (MMP-1, MMP-2, MMP-3, MMP-9, etc). Depending on the activation method, MMP-11 can be seen as a cascade of active forms. By immunoblotting against the reduced protein, the antibody reacts with bands at 58 kDa and 45 kDa and a series of further cleaved active forms. It also reacts with non-reduced MMP-11.

The matrix metalloproteinases (MMPs) are a family of at least eighteen secreted and membrane-bound zincendopeptidases. Collectively, these enzymes can degrade all the components of the extracellular matrix, including fibrillar and non-fibrillar collagens, fibronectin, laminin and basement membrane glycoproteins. In general, a signal peptide, a propeptide, and a catalytic domain containing the highly conserved zinc-binding site characterizes the structure of the MMPs. In addition, fibronectin-like repeats, a hinge region, and a C-terminal hemopexin-like domain allow categorization of MMPs into the collagenase, gelatinase, stomelysin and membrane-type MMP subfamilies. 1-3 MMPs contain the motif His-Glu-X-X-His (X represents any amino acid) that binds zinc in the catalytic site, as well as another zinc molecule and two calcium molecules structurally. They fall within the matrixin subfamily and are EC designated 3.4.24.x. This group also contains astacin, reprolysin, and serralysin, as well as other

more divergent metalloproteinases. All MMPs are synthesized as proenzymes, and most of them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is a critical step that leads to extracellular matrix breakdown.

MMPs are considered to play an important role in wound healing, apoptosis, bone elongation, embryo development, uterine involution, angiogenesis, ⁴ and tissue remodeling, and in diseases such as multiple sclerosis, ^{2, 5} Alzheimer's, ² malignant gliomas, ² lupus, arthritis, periodontis, glumerulonephritis, atherosclerosis, tissue ulceration, and in cancer cell invasion and metastasis. ⁶ Numerous studies have shown that there is a close association between expression of various members of the MMP family by tumors and their proliferative and invasive behavior and metastaic potential.

The tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring proteins that specifically inhibit matrix metalloproteinases and regulate extracellular matrix turnover and tissue remodeling by forming tightbinding inhibitory complexes with the MMPs. Thus, TIMPs maintain the balance between matrix destruction and formation. An imbalance between MMPs and the associated TIMPs may play a significant role in the invasive phenotype of malignant tumors. MMPs and TIMPs can be divided into two groups with respect to gene expression: the majority exhibit inducible expression and a small number are produced constitutively or are expressed at very low levels and are not inducible. Among agents that induce MMP and TIMP production are the inflammatory cytokines TNF- α and IL-1B. A marked cell type specificity is a hallmark of both MMP and TIMP gene expression (i.e., a limited number of cell types can be induced to make these proteins).

Matrix Metalloproteinase-11 (MMP-11, stromelysin-3) was first cloned from breast tumors. The normal cells surrounding the carcinoma express MMP-11, rather than the carcinoma cells themselves. The sequence for MMP-11 is most similar to MMP-3, but MMP-11 seems to have much more restricted substrate specificity or much lower activity than MMP-3

(stromelysin-1). In addition, MMP-11 contains a furincleavage site that MMP-3 lacks. MMP-11 has been detected in a variety of cells, including dermal and lung fibroblasts and many tumor cell lines. Most cell types do not constitutively produce MMP-11, but it has been found in lung and gingival fibroblasts, breast tumor and osteosarcoma cell lines when these cells are stimulated with EGF.

MMP-11 is secreted in a glycosylated form and the zymogen is approximately 64 kDa. Depending on the activation method, MMP-11 can be seen as a cascade of active forms. In addition to stimulation by EGF, MMP-11 expression can also be stimulated by retinoic acid. The human MMP-11 gene has the chromosomal location of 22q11.2.

Reagent

Rabbit Anti-MMP-11, N-Terminal, is supplied in 0.01 M phosphate buffered saline, pH 7.4, containing 50 % glycerol and 0.1 % sodium azide.

Protein concentration is approximately 1 mg/ml.

Precautions and Disclaimer

Due to the sodium azide content a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2 °C to 8 °C for up to six months. For extended storage, the solution may be stored 0 °C to –20 °C. The antibody is supplied with 50 % glycerol to prevent freezing. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Product Profile

A working dilution of 1:1,000 is determined by immunoblotting using a concentrated cell culture media from a stimulated human cell line, an alkaline phosphatase conjugated secondary antibody, and BCIP/NBT as substrate. Higher antibody concentrations may be necessary for non-human samples.

Note: Since cell types differ greatly in the quantity of MMP-11 produced, the conditioned media may require concentration to visualize the bands by immunoblotting.

In order to obtain best results and assay sensitivity in different techniques and preparations we recommend determining optimum working dilutions by titration assay.

References

- Borkakoti, N., Matrix metalloproteases: variations on a theme. Prog. Biophy. Mol. Biol., 70, 73 (1998).
- Yong, V.W., et al., Matrix metalloproteinases and diseases of the CNS. Trends in Neuroscience, 21, 75 (1998).
- 3. Kähäri, V.M., and Saarialho-Kere, U., Matrix metalloproteinases in skin. Exp. Dermatol., **6**, 199 (1997).
- Halpert, I., et al., Matrilysin is expressed by lipidladen macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci., USA, 93, 9748 (1996).
- Chandler, S., et al., Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol., 72, 155 (1997).
- Birkedal-Hansen, H., et al., Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med., 4, 197 (1993).
- Basset, P., et al., A Novel Metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704 (1990).
- Guerin, E., et al., Stromelysin-3 induction and interstitial collagenase repression by retinoic acid: Therapeutic implication of receptor-selective retinoids dissociating transactivation and AP-1mediated transrepression. J. Biol. Chem., 272, 11088-11095 (1997).
- 9. Levy, A., et al., Assignment of the human stromelysin-3 gene to the q11.2 region of chromosome 22. Genomics, **13**, 881-883 (1992).

kaa 10/00